Literature DB >> 17473211

A mosaic fiber adenovirus serotype 5 vector containing reovirus sigma 1 and adenovirus serotype 3 knob fibers increases transduction in an ovarian cancer ex vivo system via a coxsackie and adenovirus receptor-independent pathway.

Yuko Tsuruta1, Larisa Pereboeva, Joel N Glasgow, Daniel T Rein, Yosuke Kawakami, Ronald D Alvarez, Rodney P Rocconi, Gene P Siegal, Paul Dent, Paul B Fisher, David T Curiel.   

Abstract

PURPOSE: Adenovirus serotype 5 (Ad5) has been used for gene therapy with limited success due to insufficient infectivity in cells with low expression of the primary receptor, the coxsackie and adenovirus receptor (CAR). Evidence that adenovirus serotype receptors other than CAR may be of use was presented in previous studies that showed that the Ad3 receptor is expressed at high levels in ovarian cancer cells. We hypothesized that combined use of unique chimeric fibers in the context of novel mosaic adenovirus vectors would enhance infectivity via non-CAR pathways in ovarian cancer cells. EXPERIMENTAL
DESIGN: We constructed and characterized Ad5 vectors that use Ad3 knob and reovirus fibers to generate a mosaic fiber virion. Serotype 3 Dearing reovirus uses a fiber-like sigma 1 protein to infect cells expressing sialic acid and junction adhesion molecule 1. We therefore constructed a mosaic fiber Ad5 vector, designated Ad5/3-sigma 1, encoding two fibers: a sigma 1 chimeric fiber and the chimeric Ad5/3 fiber composed of an Ad3 knob.
RESULTS: Functionally, Ad5/3-sigma 1 used sialic acid, junction adhesion molecule 1, and Ad3 receptor for cell transduction and achieved maximum infectivity enhancement in ovarian cancer cells with low CAR expression. Furthermore, Ad5/3-sigma 1 achieved infectivity enhancement in primary tissue slices of human ovarian tumor.
CONCLUSIONS: We have developed a new type of Ad5 vector with the novel tropism, possessing fibers from Ad3 and reovirus, which exhibits enhanced infectivity via CAR-independent pathway(s). In addition, the flexible genetic platform of vector allows different combination of fiber variants that can be incorporated within the same particle.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17473211      PMCID: PMC2211731          DOI: 10.1158/1078-0432.CCR-06-2706

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  24 in total

1.  Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells.

Authors:  T P Cripe; E J Dunphy; A D Holub; A Saini; N H Vasi; Y Y Mahller; M H Collins; J D Snyder; V Krasnykh; D T Curiel; T J Wickham; J DeGregori; J M Bergelson; M A Currier
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

2.  Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein.

Authors:  Natalya Belousova; Valentina Krendelchtchikova; David T Curiel; Victor Krasnykh
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

3.  Fiber-mosaic adenovirus as a novel approach to design genetically modified adenoviral vectors.

Authors:  Larisa Pereboeva; Svetlana Komarova; Parameshwar J Mahasreshti; David T Curiel
Journal:  Virus Res       Date:  2004-09-15       Impact factor: 3.303

4.  Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism.

Authors:  V N Krasnykh; G V Mikheeva; J T Douglas; D T Curiel
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

5.  Mutations in type 3 reovirus that determine binding to sialic acid are contained in the fibrous tail domain of viral attachment protein sigma1.

Authors:  J D Chappell; V L Gunn; J D Wetzel; G S Baer; T S Dermody
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

6.  Junction adhesion molecule is a receptor for reovirus.

Authors:  E S Barton; J C Forrest; J L Connolly; J D Chappell; Y Liu; F J Schnell; A Nusrat; C A Parkos; T S Dermody
Journal:  Cell       Date:  2001-02-09       Impact factor: 41.582

7.  Selectivity of TAG-72-targeted adenovirus gene transfer to primary ovarian carcinoma cells versus autologous mesothelial cells in vitro.

Authors:  F J Kelly; C R Miller; D J Buchsbaum; J Gomez-Navarro; M N Barnes; R D Alvarez; D T Curiel
Journal:  Clin Cancer Res       Date:  2000-11       Impact factor: 12.531

8.  Oncolytic reovirus against ovarian and colon cancer.

Authors:  Kensuke Hirasawa; Sandra G Nishikawa; Kara L Norman; Tommy Alain; Anna Kossakowska; Patrick W K Lee
Journal:  Cancer Res       Date:  2002-03-15       Impact factor: 12.701

9.  Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors.

Authors:  J T Douglas; M Kim; L A Sumerel; D E Carey; D T Curiel
Journal:  Cancer Res       Date:  2001-02-01       Impact factor: 12.701

10.  A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity.

Authors:  Tyler O Kirby; Angel Rivera; Daniel Rein; Minghui Wang; Ilya Ulasov; Martina Breidenbach; Manjula Kataram; Juan L Contreras; Carlos Krumdieck; Masato Yamamoto; Marianne G Rots; Hidde J Haisma; Ronald D Alvarez; Parameshwar J Mahasreshti; David T Curiel
Journal:  Clin Cancer Res       Date:  2004-12-15       Impact factor: 12.531

View more
  12 in total

1.  A conditionally replicative adenovirus, CRAd-S-pK7, can target endometriosis with a cell-killing effect.

Authors:  A A V Paupoo; Z B Zhu; M Wang; D T Rein; A Starzinski-Powitz; D T Curiel
Journal:  Hum Reprod       Date:  2010-06-23       Impact factor: 6.918

Review 2.  Chapter two--Adenovirus strategies for tissue-specific targeting.

Authors:  Matthew S Beatty; David T Curiel
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

3.  Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer.

Authors:  Otto Hemminki; Iulia Diaconu; Vincenzo Cerullo; Saila K Pesonen; Anna Kanerva; Timo Joensuu; Kalevi Kairemo; Leena Laasonen; Kaarina Partanen; Lotta Kangasniemi; Andre Lieber; Sari Pesonen; Akseli Hemminki
Journal:  Mol Ther       Date:  2012-08-07       Impact factor: 11.454

Review 4.  Retargeting adenoviruses for therapeutic applications and vaccines.

Authors:  Michael A Barry; Jeffrey D Rubin; Shao-Chia Lu
Journal:  FEBS Lett       Date:  2020-02-03       Impact factor: 4.124

5.  Adenoviral vector-based strategies for cancer therapy.

Authors:  Anurag Sharma; Manish Tandon; Dinesh S Bangari; Suresh K Mittal
Journal:  Curr Drug ther       Date:  2009-05-01

Review 6.  Developing an effective gene therapy for prostate cancer: New technologies with potential to translate from the laboratory into the clinic.

Authors:  Rupesh Dash; Belal Azab; Xue-Ning Shen; Upneet K Sokhi; Siddik Sarkar; Zhao-zhong Su; Xiang-Yang Wang; Pier Paolo Claudio; Paul Dent; Igor P Dmitriev; David T Curiel; Steven Grant; Devanand Sarkar; Paul B Fisher
Journal:  Discov Med       Date:  2011-01       Impact factor: 2.970

7.  Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the Apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells.

Authors:  Belal Azab; Rupesh Dash; Swadesh K Das; Sujit K Bhutia; Xue-Ning Shen; Bridget A Quinn; Siddik Sarkar; Xiang-Yang Wang; Michael Hedvat; Igor P Dmitriev; David T Curiel; Steven Grant; Paul Dent; John C Reed; Maurizio Pellecchia; Devanand Sarkar; Paul B Fisher
Journal:  J Cell Physiol       Date:  2012-05       Impact factor: 6.384

8.  Derivation of a triple mosaic adenovirus for cancer gene therapy.

Authors:  Yizhe Tang; Hongju Wu; Hideyo Ugai; Qiana L Matthews; David T Curiel
Journal:  PLoS One       Date:  2009-12-31       Impact factor: 3.240

Review 9.  Cancer terminator viruses (CTV): A better solution for viral-based therapy of cancer.

Authors:  Luni Emdad; Swadesh K Das; Xiang-Yang Wang; Devanand Sarkar; Paul B Fisher
Journal:  J Cell Physiol       Date:  2018-02-27       Impact factor: 6.384

10.  Fiber-modified adenovirus for central nervous system Parkinson's disease gene therapy.

Authors:  Travis B Lewis; Joel N Glasgow; Ashley S Harms; David G Standaert; David T Curiel
Journal:  Viruses       Date:  2014-08-21       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.